A First In Human Study Of PF-00184562 In Healthy Volunteers

Pfizer

Status and phase: Completed; Phase 1

Conditions: Schizophrenia

Treatments: Drug: PF-00184562; Drug: Olanzapine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00150215

A6241001

Details and patient eligibility

About

The purposes of this study are:

• To determine the safety, tolerability and pharmacokinetics of single doses of PF-00184562; and
• To explore the exposure-response relationship of neuropsychometric and tolerability measures of PF-00184562 compared to olanzapine.

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy male or female subjects of non-childbearing potential

Exclusion criteria

• Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, pancreatic, psychiatric, neurologic, active infections, immunological, or allergic disease (including drug allergies and seasonal allergies at time of dosing).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind